Pfizer doses first participant in phase 3 study evaluating anti-TFPI investigational therapy

[cafead]

via Pfizer announced that the first participant has been dosed in the Phase 3 BASIS study of marstacimab (PF-06741086), an anti-tissue factor pathway inhibitor (anti-TFPI) being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.

article source